| 38.35 Delayed Data As of Dec 17 |  -0.80 / -2.04%Today’s Change | 32.69 Today|||52-Week Range 41.78 | +10.52% Year-to-Date |
| Merck to Acquire Europe's Antelliq Group for $2.4 Billion Dec 17 / Zacks.com - Paid Partner Content | AstraZeneca's Imfinzi Fails in Head and Neck Cancer Study Dec 07 / Zacks.com - Paid Partner Content |
| Pharma Stock Roundup: AZN, RHHBY Cancer Drugs, LLY, BMY New Deals in Focus Dec 14 / Zacks.com - Paid Partner Content | Inovio (INO) to Receive Milestone Payment From AstraZeneca Dec 05 / Zacks.com - Paid Partner Content |
| Novartis Presents Additional Data on Breast Cancer Candidate Dec 07 / Zacks.com - Paid Partner Content |
| Previous close | 39.15 |
| Today’s open | 39.20 |
| Day’s range | 38.17 - 39.28 |
| Volume | 4,360,587 |
| Average volume (3 months) | 4,469,074 |
| Market cap | $101.9B |
| Earnings growth (last year) | -13.30% |
| Earnings growth (this year) | -17.39% |
| Earnings growth (next 5 years) | +10.00% |
| Revenue growth (last year) | -1.03% |
| P/E ratio | 40.1 |
| Price/Sales | 3.87 |
| Price/Book | 6.81 |
| Today’s change | Today’s % change | |
|---|---|---|
| GSKGlaxoSmithKline | -0.54 | -1.44% |
| SNYSanofi | -0.47 | -1.07% |
| LLYEli Lilly and Co | -3.57 | -3.19% |
| ABTAbbott Laboratories | -1.01 | -1.43% |
| Next reporting date | February 14, 2019 |
| EPS forecast (this quarter) | $0.82 |
| Annual revenue (last year) | $22.7B |
| Annual profit (last year) | $3.0B |
| Net profit margin | 13.36% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Pascal Soriot |
Executive VP-Operations & Information Technology Pam P. Cheng |
Corporate headquarters Cambridge, Cambridgeshire |
